Skip to main
NUVB
NUVB logo

Nuvation Bio (NUVB) Stock Forecast & Price Target

Nuvation Bio (NUVB) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Nuvation Bio Inc is strategically positioned in the oncology sector with its lead candidate, taletrectinib, demonstrating significant efficacy, as evidenced by an 88.8% confirmed overall response rate and a median progression-free survival of 45.6 months in TKI-naive ROS1+ NSCLC patients. The company's proactive engagement with the FDA regarding safety signals enhances confidence in its clinical trial ethics, while successful approval in China and a revised probability of success for taletrectinib to 60% signals a strong regulatory outlook. Additionally, the anticipated market penetration of 35% due to superior efficacy and updated treatment guidelines presents a compelling growth trajectory for Nuvation Bio's drug portfolio, further supported by its revenue-generating out-licensing agreements.

Bears say

Nuvation Bio Inc faces significant risks that contribute to a negative outlook for its stock, particularly related to its clinical pipeline, including potential negative clinical data and delays in obtaining regulatory approvals for its candidate taletrectinib. The company reported a net loss of $0.15 per share for the fourth quarter of 2024 and is projected to incur a larger net loss of $0.71 per share in 2025, reflecting worsening financial expectations. Compounding these concerns, the company might confront challenges in achieving anticipated commercial uptake of its products due to increasing competition and market dynamics, along with the possibility of long-term dilution risk.

Nuvation Bio (NUVB) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvation Bio (NUVB) Forecast

Analysts have given Nuvation Bio (NUVB) a Buy based on their latest research and market trends.

According to 8 analysts, Nuvation Bio (NUVB) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.81, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.81, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvation Bio (NUVB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.